Joseph G. Pressey · Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model
Follow
Article1 min read·Published May 2013Older

Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · May 2013 · 1 min read

In brief

In brief

This preclinical study demonstrates that rapamycin achieves >95% tumor growth inhibition in a rhabdomyosarcoma xenograft model by simultaneously blocking mTOR and hedgehog signaling pathways. The dual pathway inhibition reduced proliferation markers, enhanced apoptosis, and decreased tumor invasiveness, suggesting a promising targeted therapy approach for metastatic and refractory RMS patients.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Rhabdomyosarcomas (RMS) represent the most common childhood soft-tissue sarcoma. Over the past few decades outcomes for low and intermediate risk RMS patients have slowly improved while patients with metastatic or relapsed RMS still face a grim prognosis. New chemotherapeutic agents or combinations of chemotherapies have largely failed to improve the outcome. Based on the identification of novel molecular targets, potential therapeutic approaches in RMS may offer a decreased reliance on conventional chemotherapy. Thus, identification of effective therapeutic agents that specifically target relevant pathways may be particularly beneficial for patients with metastatic and refractory RMS. The PI3K/AKT/mTOR pathway has been found to be a potentially attractive target in RMS therapy. In this study, we provide evidence that rapamycin (sirolimus) abrogates growth of RMS development in a RMS xenograft mouse model. As compared to a vehicle-treated control group, more than 95% inhibition in tumor growth was observed in mice receiving parenteral administration of rapamycin. The residual tumors in rapamycin-treated group showed significant reduction in the expression of biomarkers indicative of proliferation and tumor invasiveness. These tumors also showed enhanced apoptosis. Interestingly, the mechanism by which rapamycin diminished RMS tumor growth involved simultaneous inhibition of mTOR and hedgehog (Hh) pathways. Diminution in these pathways in this model of RMS also inhibited epith

Statements in this article

  1. Rhabdomyosarcomas represent the most common childhood soft-tissue sarcoma.

    Established
  2. Patients with metastatic or relapsed rhabdomyosarcoma face a grim prognosis despite improvements in outcomes for low and intermediate risk patients.

    Established
  3. New chemotherapeutic agents or combinations of chemotherapies have largely failed to improve outcomes in rhabdomyosarcoma.

    Established
  4. The PI3K/AKT/mTOR pathway has been found to be a potentially attractive target in rhabdomyosarcoma therapy.

    Established
  5. Rapamycin abrogates growth of rhabdomyosarcoma development in a xenograft mouse model.

    Research
  6. More than 95% inhibition in tumor growth was observed in mice receiving parenteral administration of rapamycin compared to vehicle-treated controls.

    Research
  7. Residual tumors in rapamycin-treated mice showed significant reduction in the expression of biomarkers indicative of proliferation and tumor invasiveness.

    Research
  8. Tumors in rapamycin-treated mice showed enhanced apoptosis.

    Research
  9. Rapamycin diminished rhabdomyosarcoma tumor growth through simultaneous inhibition of mTOR and hedgehog pathways.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.